Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.
A major meta-analysis of 19 randomized trials involving 123,940 participants found that only six side effects are actually caused by statins, challenging long-standing concerns about the drugs' safety profile.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07145801 |
Y-90 Treatment Response Using Transarterial Radioembolization |
RECRUITING | PHASE2 |
| NCT06486454 |
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) |
RECRUITING | |
| NCT06342414 |
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer |
RECRUITING |
